Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 30, 2015 19:00 ET | Source: MediciNova, Inc.

MediciNova Announces the Completion of Enrollment in Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence

LA JOLLA, Calif., June 30, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 24, 2015 09:00 ET | Source: MediciNova, Inc.

MediciNova Announces Presentation of Interim Data from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence at the 38th Annual RSA (Research Society on Alcoholism) Scientific Meeting

LA JOLLA, Calif., June 24, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 16, 2015 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces New Article Published on MN-166 (ibudilast) in Addiction Biology

LA JOLLA, Calif., June 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 12, 2015 06:00 ET | Source: MediciNova, Inc.

MediciNova Announces Randomization of 255 Subjects Completed in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., June 12, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
June 03, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces FDA Granted Orphan Drug Designation to MN-166 (ibudilast) for Krabbe Disease

LA JOLLA, Calif., June 3, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
May 07, 2015 08:00 ET | Source: MediciNova, Inc.

MediciNova Announces Full Enrollment in Phase 2b Trial of MN-166 (ibudilast) in Progressive MS

LA JOLLA, Calif., May 7, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code...
April 23, 2015 19:00 ET | Source: MediciNova, Inc.

Baseline Characteristics of 228 Subjects Enrolled in MediciNova's Phase 2b Trial of MN-166 (ibudilast) in Progressive MS Presented at the American Academy of Neurology (AAN) 67th Annual Meeting

LA JOLLA, Calif., April 23, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 21, 2015 13:45 ET | Source: MediciNova, Inc.

MediciNova Announces Positive Interim Safety Data From Clinical Trial of MN-166 (ibudilast) in ALS

LA JOLLA, Calif., April 21, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 16, 2015 08:30 ET | Source: MediciNova, Inc.

Tokyo Stock Exchange Announces New Rule Affecting Trading of MediciNova Stock in Japan

LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
April 16, 2015 08:00 ET | Source: MediciNova, Inc.

FDA Grants Fast Track Designation for MediciNova's MN-001 (tipelukast) for the Treatment of NASH with Fibrosis

LA JOLLA, Calif., April 16, 2015 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...